The Latest Analyst Ratings For Ionis Pharmaceuticals
Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Ionis Pharmaceuticals (NASDAQ:IONS) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 1 | 1 | 0 | 0 |
| Last 30D | 2 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $66.17, a high estimate of $82.00, and a low estimate of $53.00. Marking an increase of 14.09%, the current average surpasses the previous average price target of $58.00.
Exploring Analyst Ratings: An In-Depth Overview
The perception of Ionis Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jason Gerberry | B of A Securities | Raises | Buy | $67.00 | $64.00 |
| Akash Tewari | Jefferies | Raises | Buy | $75.00 | $29.00 |
| Paul Matteis | Stifel | Raises | Hold | $53.00 | $50.00 |
| Joseph Stringer | Needham | Maintains | Buy | $60.00 | $60.00 |
| Joseph Stringer | Needham | Maintains | Buy | $60.00 | $60.00 |
| Yanan Zhu | Wells Fargo | Lowers | Overweight | $82.00 | $85.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ionis Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ionis Pharmaceuticals compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Ionis Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Ionis Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Ionis Pharmaceuticals analyst ratings.
Unveiling the Story Behind Ionis Pharmaceuticals
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Understanding the Numbers: Ionis Pharmaceuticals's Finances
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3 months period, Ionis Pharmaceuticals faced challenges, resulting in a decline of approximately -8.45% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Ionis Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -119.5%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Ionis Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -41.8%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Ionis Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -4.96%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 4.87, caution is advised due to increased financial risk.
Understanding the Relevance of Analyst Ratings
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.